Abstract
The rapid advancement of CRISPR technology has enabled targeted epigenome editing and transcriptional modulation in the native chromatin context. However, only a few studies have reported the successful editing of the epigenome in adult animals in contrast to the rapidly growing number of in vivo genome editing over the past few years. In this review, we discuss the challenges facing in vivo epigenome editing and new strategies to overcome the huddles. The biggest challenge has been the difficulty in packaging dCas9 fusion proteins required for manipulation of epigenome into the adeno-associated virus (AAV) delivery vehicle. We review the strategies to address the AAV packaging issue, including small dCas9 orthologues, truncated dCas9 mutants, a split-dCas9 system, and potent truncated effector domains. We discuss the dCas9 conjugation strategies to recruit endogenous chromatin modifiers and remodelers to specific genomic loci, and recently developed methods to recruit multiple copies of the dCas9 fusion protein, or to simultaneous express multiple gRNAs for robust epigenome editing or synergistic transcriptional modulation. The use of Cre-inducible dCas9-expressing mice or a genetic cross between dCas9- and sgRNA-expressing flies has also helped overcome the transgene delivery issue. We provide perspective on how a combination use of these strategies can facilitate in vivo epigenome editing and transcriptional modulation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amabile A, Migliara A, Capasso P, Biffi M, Cittaro D, Naldini L, Lombardo A (2016) Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing. Cell 167:219–232. https://doi.org/10.1016/j.cell.2016.09.006
Batra R, Nelles DA, Pirie E, Blue SM, Marina RJ, Wang H, Chaim IA, Thomas JD, Zhang N, Nguyen V, Aigner S, Markmiller S, Xia G, Corbett KD, Swanson MS, Yeo GW (2017) Elimination of toxic microsatellite repeat expansion RNA by RNA-targeting Cas9. Cell 170:899–912. https://doi.org/10.1016/j.cell.2017.07.010
Bieberstein NI, Kozakova E, Huranova M, Thakur PK, Krchnakova Z, Krausova M, Carrillo Oesterreich F, Stanek D (2016) TALE-directed local modulation of H3K9 methylation shapes exon recognition. Sci Rep 6:29961. https://doi.org/10.1038/srep29961
Black JB, Adler AF, Wang HG, D’Ippolito AM, Hutchinson HA, Reddy TE, Pitt GS, Leong KW, Gersbach CA (2016) Targeted epigenetic remodeling of endogenous loci by CRISPR/Cas9-based transcriptional activators directly converts fibroblasts to neuronal cells. Cell Stem Cell 19:406–414. https://doi.org/10.1016/j.stem.2016.07.001
Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT (2016) Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. Proc Natl Acad Sci USA 113:E3892–E3900. https://doi.org/10.1073/pnas.1600582113
Braun SMG, Kirkland JG, Chory EJ, Husmann D, Calarco JP, Crabtree GR (2017) Rapid and reversible epigenome editing by endogenous chromatin regulators. Nat Commun 8:560. https://doi.org/10.1038/s41467-017-00644-y
Buning H, Huber A, Zhang L, Meumann N, Hacker U (2015) Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol 24:94–104. https://doi.org/10.1016/j.coph.2015.08.002
Cano-Rodriguez D, Gjaltema RA, Jilderda LJ, Jellema P, Dokter-Fokkens J, Ruiters MH, Rots MG (2016) Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner. Nat Commun 7:12284. https://doi.org/10.1038/ncomms12284
Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, Iyer EP, Lin S, Kiani S, Guzman CD, Wiegand DJ, Ter-Ovanesyan D, Braff JL, Davidsohn N, Housden BE, Perrimon N, Weiss R, Aach J, Collins JJ, Church GM (2015) Highly efficient Cas9-mediated transcriptional programming. Nat Methods 12:326–328. https://doi.org/10.1038/nmeth.3312
Chen B, Gilbert LA, Cimini BA, Schnitzbauer J, Zhang W, Li GW, Park J, Blackburn EH, Weissman JS, Qi LS, Huang B (2013) Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155:1479–1491. https://doi.org/10.1016/j.cell.2013.12.001
Chen F, Ding X, Feng Y, Seebeck T, Jiang Y, Davis GD (2017) Targeted activation of diverse CRISPR-Cas systems for mammalian genome editing via proximal CRISPR targeting. Nat Commun 8:14958. https://doi.org/10.1038/ncomms14958
Chew WL, Tabebordbar M, Cheng JK, Mali P, Wu EY, Ng AH, Zhu K, Wagers AJ, Church GM (2016) A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods 13:868–874. https://doi.org/10.1038/nmeth.3993
Cho SW, Kim S, Kim JM, Kim JS (2013) Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31:230–232. https://doi.org/10.1038/nbt.2507
Colella P, Ronzitti G, Mingozzi F (2018) Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev 8:87–104. https://doi.org/10.1016/j.omtm.2017.11.007
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. https://doi.org/10.1126/science.1231143
Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, Zhang F (2017) RNA editing with CRISPR-Cas13. Science 358:1019–1027. https://doi.org/10.1126/science.aaq0180
Dong F, Xie K, Chen Y, Yang Y, Mao Y (2017) Polycistronic tRNA and CRISPR guide-RNA enables highly efficient multiplexed genome engineering in human cells. Biochem Biophys Res Commun 482:889–895. https://doi.org/10.1016/j.bbrc.2016.11.129
Dugar G, Leenay RT, Eisenbart SK, Bischler T, Aul BU, Beisel CL, Sharma CM (2018) CRISPR RNA-dependent binding and cleavage of endogenous RNAs by the Campylobacter jejuni Cas9. Mol Cell 69:893–905. https://doi.org/10.1016/j.molcel.2018.01.032
Ewen-Campen B, Yang-Zhou D, Fernandes VR, Gonzalez DP, Liu LP, Tao R, Ren X, Sun J, Hu Y, Zirin J, Mohr SE, Ni JQ, Perrimon N (2017) Optimized strategy for in vivo Cas9-activation in Drosophila. Proc Natl Acad Sci USA 114:9409–9414. https://doi.org/10.1073/pnas.1707635114
Feng Q, Wang H, Ng HH, Erdjument-Bromage H, Tempst P, Struhl K, Zhang Y (2002) Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 12:1052–1058
Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suner D, Cigudosa JC, Urioste M, Benitez J, Boix-Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P, Vaag A, Stephan Z, Spector TD, Wu YZ, Plass C, Esteller M (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 102:10604–10609. https://doi.org/10.1073/pnas.0500398102
Gaj T, Gersbach CA, Barbas CF III (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31:397–405. https://doi.org/10.1016/j.tibtech.2013.04.004
Gallego-Bartolome J, Gardiner J, Liu W, Papikian A, Ghoshal B, Kuo HY, Zhao JM, Segal DJ, Jacobsen SE (2018) Targeted DNA demethylation of the Arabidopsis genome using the human TET1 catalytic domain. Proc Natl Acad Sci USA 115:E2125–E2134. https://doi.org/10.1073/pnas.1716945115
Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154:442–451. https://doi.org/10.1016/j.cell.2013.06.044
Grimm D, Buning H (2017) Small but increasingly mighty: latest advances in AAV vector research, design, and evolution. Hum Gene Ther 28:1075–1086. https://doi.org/10.1089/hum.2017.172
Guo JU, Su Y, Zhong C, Ming GL, Song H (2011) Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145:423–434. https://doi.org/10.1016/j.cell.2011.03.022
Gupta RM, Musunuru K (2014) Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest 124:4154–4161. https://doi.org/10.1172/JCI72992
Hao N, Shearwin KE, Dodd IB (2017) Programmable DNA looping using engineered bivalent dCas9 complexes. Nat Commun 8:1628. https://doi.org/10.1038/s41467-017-01873-x
Hatchwell E, Greally JM (2007) The potential role of epigenomic dysregulation in complex human disease. Trends Genet 23:588–595. https://doi.org/10.1016/j.tig.2007.08.010
Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM, Kormaksson M, MacKerell AD Jr, Xue F, Mason CE, Hiebert SW, Prive GG, Cerchietti L, Bardwell VJ, Elemento O, Melnick A (2013) A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Rep 4:578–588. https://doi.org/10.1016/j.celrep.2013.06.016
He Y, Zhang T, Yang N, Xu M, Yan L, Wang L, Wang R, Zhao Y (2017) Self-cleaving ribozymes enable the production of guide RNAs from unlimited choices of promoters for CRISPR/Cas9 mediated genome editing. J Genet Genomics 44:469–472. https://doi.org/10.1016/j.jgg.2017.08.003
Hilton IB, D’Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA (2015) Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol 33:510–517. https://doi.org/10.1038/nbt.3199
Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262–1278. https://doi.org/10.1016/j.cell.2014.05.010
Huang YH, Su J, Lei Y, Brunetti L, Gundry MC, Zhang X, Jeong M, Li W, Goodell MA (2017) DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A. Genome Biol 18:176. https://doi.org/10.1186/s13059-017-1306-z
Jia Y, Xu RG, Ren X, Ewen-Campen B, Rajakumar R, Zirin J, Yang-Zhou D, Zhu R, Wang F, Mao D, Peng P, Qiao HH, Wang X, Liu LP, Xu B, Ji JY, Liu Q, Sun J, Perrimon N, Ni JQ (2018) Next-generation CRISPR/Cas9 transcriptional activation in Drosophila using flySAM. Proc Natl Acad Sci USA 1:1. https://doi.org/10.1073/pnas.1800677115
Jin F, Li Y, Dixon JR, Selvaraj S, Ye Z, Lee AY, Yen CA, Schmitt AD, Espinoza CA, Ren B (2013) A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature 503:290–294. https://doi.org/10.1038/nature12644
Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, Sanjana NE, Zhang F (2017) Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc 12:828–863. https://doi.org/10.1038/nprot.2017.016
Kearns NA, Pham H, Tabak B, Genga RM, Silverstein NJ, Garber M, Maehr R (2015) Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods 12:401–403. https://doi.org/10.1038/nmeth.3325
Kim E, Koo T, Park SW, Kim D, Kim K, Cho HY, Song DW, Lee KJ, Jung MH, Kim S, Kim JH, Kim JH, Kim JS (2017) In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat Commun 8:14500. https://doi.org/10.1038/ncomms14500
Klann TS, Black JB, Chellappan M, Safi A, Song L, Hilton IB, Crawford GE, Reddy TE, Gersbach CA (2017) CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nat Biotechnol 35:561–568. https://doi.org/10.1038/nbt.3853
Koike-Yusa H, Li Y, Tan EP, Velasco-Herrera MDC, Yusa K (2013) Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol 32:267–273. https://doi.org/10.1038/nbt.2800
Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517:583–588. https://doi.org/10.1038/nature14136
Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD (2018) Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173:665–676. https://doi.org/10.1016/j.cell.2018.02.033
Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, Ziller MJ, Amin V, Whitaker JW, Schultz MD, Ward LD, Sarkar A, Quon G, Sandstrom RS, Eaton ML, Wu YC, Pfenning AR, Wang X, Claussnitzer M, Liu Y, Coarfa C, Harris RA, Shoresh N, Epstein CB, Gjoneska E, Leung D, Xie W, Hawkins RD, Lister R, Hong C, Gascard P, Mungall AJ, Moore R, Chuah E, Tam A, Canfield TK, Hansen RS, Kaul R, Sabo PJ, Bansal MS, Carles A, Dixon JR, Farh KH, Feizi S, Karlic R, Kim AR, Kulkarni A, Li D, Lowdon R, Elliott G, Mercer TR, Neph SJ, Onuchic V, Polak P, Rajagopal N, Ray P, Sallari RC, Siebenthall KT, Sinnott-Armstrong NA, Stevens M, Thurman RE, Wu J, Zhang B, Zhou X, Beaudet AE, Boyer LA, De Jager PL, Farnham PJ, Fisher SJ, Haussler D, Jones SJ, Li W, Marra MA, McManus MT, Sunyaev S, Thomson JA, Tlsty TD, Tsai LH, Wang W, Waterland RA, Zhang MQ, Chadwick LH, Bernstein BE, Costello JF, Ecker JR, Hirst M, Meissner A, Milosavljevic A, Ren B, Stamatoyannopoulos JA, Wang T, Kellis M (2015) Integrative analysis of 111 reference human epigenomes. Nature 518:317–330. https://doi.org/10.1038/nature14248
Kungulovski G, Nunna S, Thomas M, Zanger UM, Reinhardt R, Jeltsch A (2015) Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintained. Epigenetics Chromatin 8:12. https://doi.org/10.1186/s13072-015-0002-z
Kwon DY, Zhao YT, Lamonica JM, Zhou Z (2017) Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC. Nat Commun 8:15315. https://doi.org/10.1038/ncomms15315
Lei Y, Zhang X, Su J, Jeong M, Gundry MC, Huang YH, Zhou Y, Li W, Goodell MA (2017) Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein. Nat Commun 8:16026. https://doi.org/10.1038/ncomms16026
Li Z, Zhang D, Xiong X, Yan B, Xie W, Sheen J, Li JF (2017) A potent Cas9-derived gene activator for plant and mammalian cells. Nat Plants 3:930–936. https://doi.org/10.1038/s41477-017-0046-0
Liao HK, Hatanaka F, Araoka T, Reddy P, Wu MZ, Sui Y, Yamauchi T, Sakurai M, O’Keefe DD, Nunez-Delicado E, Guillen P, Campistol JM, Wu CJ, Lu LF, Esteban CR, Izpisua Belmonte JC (2017) In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation. Cell 171:1495–1507. https://doi.org/10.1016/j.cell.2017.10.025
Lin S, Ewen-Campen B, Ni X, Housden BE, Perrimon N (2015) In vivo transcriptional activation using CRISPR/Cas9 in Drosophila. Genetics 201:433–442. https://doi.org/10.1534/genetics.115.181065
Liszczak GP, Brown ZZ, Kim SH, Oslund RC, David Y, Muir TW (2017) Genomic targeting of epigenetic probes using a chemically tailored Cas9 system. Proc Natl Acad Sci USA 114:681–686. https://doi.org/10.1073/pnas.1615723114
Liu XS, Wu H, Ji X, Stelzer Y, Wu X, Czauderna S, Shu J, Dadon D, Young RA, Jaenisch R (2016) Editing DNA methylation in the mammalian genome. Cell 167:233–247. https://doi.org/10.1016/j.cell.2016.08.056
Liu P, Chen M, Liu Y, Qi LS, Ding S (2018a) CRISPR-based chromatin remodeling of the endogenous Oct4 or Sox2 locus enables reprogramming to pluripotency. Cell Stem Cell 22:252–261. https://doi.org/10.1016/j.stem.2017.12.001
Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, Hnisz D, Li CH, Yuan B, Xu C, Li Y, Vershkov D, Cacace A, Young RA, Jaenisch R (2018b) Rescue of Fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell 172:979–992. https://doi.org/10.1016/j.cell.2018.01.012
Lo CL, Choudhury SR, Irudayaraj J, Zhou FC (2017) Epigenetic editing of Ascl1 gene in neural stem cells by optogenetics. Sci Rep 7:42047. https://doi.org/10.1038/srep42047
Ma H, Naseri A, Reyes-Gutierrez P, Wolfe SA, Zhang S, Pederson T (2015) Multicolor CRISPR labeling of chromosomal loci in human cells. Proc Natl Acad Sci USA 112:3002–3007. https://doi.org/10.1073/pnas.1420024112
Ma D, Peng S, Huang W, Cai Z, Xie Z (2018) Rational design of mini-Cas9 for transcriptional activation. ACS Synth Biol 7:978–985. https://doi.org/10.1021/acssynbio.7b00404
Maeder ML, Angstman JF, Richardson ME, Linder SJ, Cascio VM, Tsai SQ, Ho QH, Sander JD, Reyon D, Bernstein BE, Costello JF, Wilkinson MF, Joung JK (2013a) Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol 31:1137–1142. https://doi.org/10.1038/nbt.2726
Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK (2013b) CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10:977–979. https://doi.org/10.1038/nmeth.2598
Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-guided human genome engineering via Cas9. Science 339:823–826. https://doi.org/10.1126/science.1232033
Martin GM (2005) Epigenetic drift in aging identical twins. Proc Natl Acad Sci USA 102:10413–10414. https://doi.org/10.1073/pnas.0504743102
Mefferd AL, Kornepati AV, Bogerd HP, Kennedy EM, Cullen BR (2015) Expression of CRISPR/Cas single guide RNAs using small tRNA promoters. RNA 21:1683–1689. https://doi.org/10.1261/rna.051631.115
Mendenhall EM, Williamson KE, Reyon D, Zou JY, Ram O, Joung JK, Bernstein BE (2013) Locus-specific editing of histone modifications at endogenous enhancers. Nat Biotechnol 31:1133–1136. https://doi.org/10.1038/nbt.2701
Mifsud B, Tavares-Cadete F, Young AN, Sugar R, Schoenfelder S, Ferreira L, Wingett SW, Andrews S, Grey W, Ewels PA, Herman B, Happe S, Higgs A, LeProust E, Follows GA, Fraser P, Luscombe NM, Osborne CS (2015) Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. Nat Genet 47:598–606. https://doi.org/10.1038/ng.3286
Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12:341–355. https://doi.org/10.1038/nrg2988
Mlambo T, Nitsch S, Hildenbeutel M, Romito M, Muller M, Bossen C, Diederichs S, Cornu TI, Cathomen T, Mussolino C (2018) Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells. Nucleic Acids Res 46:4456–4468. https://doi.org/10.1093/nar/gky171
Moreno AM, Fu X, Zhu J, Katrekar D, Shih YV, Marlett J, Cabotaje J, Tat J, Naughton J, Lisowski L, Varghese S, Zhang K, Mali P (2018) In situ gene therapy via AAV-CRISPR-Cas9-mediated targeted gene regulation. Mol Ther 26:1818–1827. https://doi.org/10.1016/j.ymthe.2018.04.017
Morgan SL, Mariano NC, Bermudez A, Arruda NL, Wu F, Luo Y, Shankar G, Jia L, Chen H, Hu JF, Hoffman AR, Huang CC, Pitteri SJ, Wang KC (2017) Manipulation of nuclear architecture through CRISPR-mediated chromosomal looping. Nat Commun 8:15993. https://doi.org/10.1038/ncomms15993
Morita S, Noguchi H, Horii T, Nakabayashi K, Kimura M, Okamura K, Sakai A, Nakashima H, Hata K, Nakashima K, Hatada I (2016) Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions. Nat Biotechnol 34:1060–1065. https://doi.org/10.1038/nbt.3658
Muzyczka N, Warrington KH Jr (2005) Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther 16:408–416. https://doi.org/10.1089/hum.2005.16.408
Nihongaki Y, Furuhata Y, Otabe T, Hasegawa S, Yoshimoto K, Sato M (2017) CRISPR-Cas9-based photoactivatable transcription systems to induce neuronal differentiation. Nat Methods 14:963–966. https://doi.org/10.1038/nmeth.4430
O’Geen H, Ren C, Nicolet CM, Perez AA, Halmai J, Le VM, Mackay JP, Farnham PJ, Segal DJ (2017) dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression. Nucleic Acids Res 45:9901–9916. https://doi.org/10.1093/nar/gkx578
Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, Olsen KM, Gregg A, Noggle S, Tessier-Lavigne M (2016) Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 533:125–129. https://doi.org/10.1038/nature17664
Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 10:973–976. https://doi.org/10.1038/nmeth.2600
Port F, Bullock SL (2016) Augmenting CRISPR applications in Drosophila with tRNA-flanked sgRNAs. Nat Methods 13:852–854. https://doi.org/10.1038/nmeth.3972
Pulecio J, Verma N, Mejia-Ramirez E, Huangfu D, Raya A (2017) CRISPR/Cas9-based engineering of the epigenome. Cell Stem Cell 21:431–447. https://doi.org/10.1016/j.stem.2017.09.006
Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173–1183. https://doi.org/10.1016/j.cell.2013.02.022
Raisner R, Kharbanda S, Jin L, Jeng E, Chan E, Merchant M, Haverty PM, Bainer R, Cheung T, Arnott D, Flynn EM, Romero FA, Magnuson S, Gascoigne KE (2018) Enhancer activity requires CBP/P300 bromodomain-dependent histone H3K27 acetylation. Cell Rep 24:1722–1729. https://doi.org/10.1016/j.celrep.2018.07.041
Ran F, Cong L, Yan W, Da S, Gootenberg J, Kriz A, Zetsche B, Shalem O, Wu X, Makarova K, Koonin E, Sharp P, Zhang F (2015) In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186–191. https://doi.org/10.1038/nature14299
Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD, Blancafort P (2012) Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 7:350–360. https://doi.org/10.4161/epi.19507
Sadhu MJ, Bloom JS, Day L, Siegel JJ, Kosuri S, Kruglyak L (2018) Highly parallel genome variant engineering with CRISPR-Cas9. Nat Genet 50:510–514. https://doi.org/10.1038/s41588-018-0087-y
Sanyal A, Lajoie BR, Jain G, Dekker J (2012) The long-range interaction landscape of gene promoters. Nature 489:109–113. https://doi.org/10.1038/nature11279
Saunderson EA, Stepper P, Gomm JJ, Hoa L, Morgan A, Allen MD, Jones JL, Gribben JG, Jurkowski TP, Ficz G (2017) Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors. Nat Commun 8:1450. https://doi.org/10.1038/s41467-017-01078-2
Senis E, Fatouros C, Grosse S, Wiedtke E, Niopek D, Mueller AK, Borner K, Grimm D (2014) CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol J 9:1402–1412. https://doi.org/10.1002/biot.201400046
Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:84–87. https://doi.org/10.1126/science.1247005
Shao J, Wang M, Yu G, Zhu S, Yu Y, Heng BC, Wu J, Ye H (2018) Synthetic far-red light-mediated CRISPR-dCas9 device for inducing functional neuronal differentiation. Proc Natl Acad Sci USA 115:E6722–E6730. https://doi.org/10.1073/pnas.1802448115
Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941–953. https://doi.org/10.1016/j.cell.2004.12.012
Spisak S, Lawrenson K, Fu, Csabai I, Cottman RT, Seo JH, Haiman C, Han Y, Lenci R, Li Q, Tisza V, Szallasi Z, Herbert ZT, Chabot M, Pomerantz M, Solymosi N, Consortium GOE, Gayther SA, Joung JK, Freedman ML (2015) CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. Nat Med 21:1357–1363. https://doi.org/10.1038/nm.3975
Stepper P, Kungulovski G, Jurkowska RZ, Chandra T, Krueger F, Reinhardt R, Reik W, Jeltsch A, Jurkowski TP (2017) Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase. Nucleic Acids Res 45:1703–1713. https://doi.org/10.1093/nar/gkw1112
Stover JD, Farhang N, Berrett KC, Gertz J, Lawrence B, Bowles RD (2017) CRISPR epigenome editing of AKAP150 in DRG neurons abolishes degenerative IVD-induced neuronal activation. Mol Ther 25:2014–2027. https://doi.org/10.1016/j.ymthe.2017.06.010
Strutt SC, Torrez RM, Kaya E, Negrete OA, Doudna JA (2018) RNA-dependent RNA targeting by CRISPR-Cas9. Elife 7:1. https://doi.org/10.7554/eLife.32724
Sun H, Li F, Liu J, Yang F, Zeng Z, Lv X, Tu M, Liu Y, Ge X, Liu C, Zhao J, Zhang Z, Qu J, Song Z, Gu F (2018) A single multiplex crRNA array for FnCpf1-mediated human genome editing. Mol Ther 26:2070–2076. https://doi.org/10.1016/j.ymthe.2018.05.021
Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33:102–106. https://doi.org/10.1038/nbt.3055
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676. https://doi.org/10.1016/j.cell.2006.07.024
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872. https://doi.org/10.1016/j.cell.2007.11.019
Thakore PI, D’Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, Crawford GE, Gersbach CA (2015) Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods 12:1143–1149. https://doi.org/10.1038/nmeth.3630
Thakore PI, Black JB, Hilton IB, Gersbach CA (2016) Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat Methods 13:127–137. https://doi.org/10.1038/nmeth.3733
Thakore PI, Kwon JB, Nelson CE, Rouse DC, Gemberling MP, Oliver ML, Gersbach CA (2018) RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. Nat Commun 9:1674. https://doi.org/10.1038/s41467-018-04048-4
Vellinga J, Smith JP, Lipiec A, Majhen D, Lemckert A, van Ooij M, Ives P, Yallop C, Custers J, Havenga M (2014) Challenges in manufacturing adenoviral vectors for global vaccine product deployment. Hum Gene Ther 25:318–327. https://doi.org/10.1089/hum.2014.007
Voets O, Tielen F, Elstak E, Benschop J, Grimbergen M, Stallen J, Janssen R, van Marle A, Essrich C (2017) Highly efficient gene inactivation by adenoviral CRISPR/Cas9 in human primary cells. PLoS ONE 12:e0182974. https://doi.org/10.1371/journal.pone.0182974
Vojta A, Dobrinic P, Tadic V, Bockor L, Korac P, Julg B, Klasic M, Zoldos V (2016) Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res 44:5615–5628. https://doi.org/10.1093/nar/gkw159
Vora S, Cheng J, Xiao R, VanDusen N, Quintino L, Pu W, Vandenberghe L, Chavez A, Church G (2018) Rational design of a compact CRISPR-Cas9 activator for AAV-mediated delivery. bioRxiv. https://doi.org/10.1101/298620
Wangensteen KJ, Wang YJ, Dou Z, Wang AW, Mosleh-Shirazi E, Horlbeck MA, Gilbert LA, Weissman JS, Berger SL, Kaestner KH (2017) Combinatorial genetics in liver repopulation and carcinogenesis with a novel in vivo CRISPR activation platform. Hepatology 68:663–676. https://doi.org/10.1002/hep.29626
Weltner J, Balboa D, Katayama S, Bespalov M, Krjutskov K, Jouhilahti EM, Trokovic R, Kere J, Otonkoski T (2018) Human pluripotent reprogramming with CRISPR activators. Nat Commun 9:2643. https://doi.org/10.1038/s41467-018-05067-x
Williams RM, Senanayake U, Artibani M, Taylor G, Wells D, Ahmed AA, Sauka-Spengler T (2018) Genome and epigenome engineering CRISPR toolkit for in vivo modulation of cis-regulatory interactions and gene expression in the chicken embryo. Development. https://doi.org/10.1242/dev.160333
Wright AV, Nunez JK, Doudna JA (2016) Biology and applications of CRISPR systems: harnessing Nature’s toolbox for genome engineering. Cell 164:29–44. https://doi.org/10.1016/j.cell.2015.12.035
Wu H, Mathioudakis N, Diagouraga B, Dong A, Dombrovski L, Baudat F, Cusack S, de Massy B, Kadlec J (2013) Molecular basis for the regulation of the H3K4 methyltransferase activity of PRDM9. Cell Rep 5:13–20. https://doi.org/10.1016/j.celrep.2013.08.035
Xu L, Zhao L, Gao Y, Xu J, Han R (2016) Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA. Nucleic Acids Res 45:e28. https://doi.org/10.1093/nar/gkw1048
Yan WX, Chong S, Zhang H, Makarova KS, Koonin EV, Cheng DR, Scott DA (2018) Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. Mol Cell 70:327–339. https://doi.org/10.1016/j.molcel.2018.02.028
Yang Q, Khoury MJ, Botto L, Friedman JM, Flanders WD (2003) Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet 72:636–649. https://doi.org/10.1086/367923
Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, Yu H, Xu C, Morizono H, Musunuru K, Batshaw ML, Wilson JM (2016) A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol 34:334–338. https://doi.org/10.1038/nbt.3469
Yeo NC, Chavez A, Lance-Byrne A, Chan Y, Menn D, Milanova D, Kuo CC, Guo X, Sharma S, Tung A, Cecchi RJ, Tuttle M, Pradhan S, Lim ET, Davidsohn N, Ebrahimkhani MR, Collins JJ, Lewis NE, Kiani S, Church GM (2018) An enhanced CRISPR repressor for targeted mammalian gene regulation. Nat Methods 15:611–616. https://doi.org/10.1038/s41592-018-0048-5
Zhang T, Gao Y, Wang R, Zhao Y (2017) Production of guide RNAs in vitro and in vivo for CRISPR using ribozymes and RNA polymerase II promoters. Bio Protoc. https://doi.org/10.21769/BioProtoc.2148
Zheng Y, Shen W, Zhang J, Yang B, Liu YN, Qi H, Yu X, Lu SY, Chen Y, Xu YZ, Li Y, Gage FH, Mi S, Yao J (2018) CRISPR interference-based specific and efficient gene inactivation in the brain. Nat Neurosci 21:447–454. https://doi.org/10.1038/s41593-018-0077-5
Zhou H, Liu J, Zhou C, Gao N, Rao Z, Li H, Hu X, Li C, Yao X, Shen X, Sun Y, Wei Y, Liu F, Ying W, Zhang J, Tang C, Zhang X, Xu H, Shi L, Cheng L, Huang P, Yang H (2018) In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice. Nat Neurosci 21:440–446. https://doi.org/10.1038/s41593-017-0060-6
Acknowledgements
This work was funded by NIH Grants (AG017242, GM104459, AG056278, and CA180126) and by the Glenn Center for the Biology of Human Aging (Paul Glenn Foundation for Medical Research) (Suh).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The author declares that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Lau, CH., Suh, Y. In vivo epigenome editing and transcriptional modulation using CRISPR technology. Transgenic Res 27, 489–509 (2018). https://doi.org/10.1007/s11248-018-0096-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11248-018-0096-8